Indevirate (antiviral payload)

1. PROGRAM OVERVIEW

Asset Name: Indevirate

Program Code: SCF-REG-HIV-INDEVIRATE-PIPE-0001

Therapeutic Area: Infectious Disease — HIV-1

Modality Class: Small-Molecule SCF-Engineered Antiviral (NCE)

Delivery Platform: Lipid–Polymer Nanoparticle (LPNP)

Development Status: IND-Enabling (Preclinical Transition)

2. INDICATION

Primary Indication:

Treatment of HIV-1 infection with focus on:

Viral load suppression
Latent reservoir reduction
Prevention of viral rebound

Target Population:

Treatment-naïve and treatment-experienced HIV patients
Patients with resistance to current ART regimens
Reservoir-reduction or functional cure cohorts

Despite advances in antiretroviral therapy:

3.1 Current Limitations

Limitation	Clinical Impact
Viral reservoir persistence	Lifelong therapy requirement
Drug resistance emergence	Treatment failure
Adherence burden	Reduced efficacy
Toxicity accumulation	Long-term complications

3.2 Strategic Gap

No approved therapy achieves durable reservoir suppression or eradication
Existing regimens rely on single-pathway inhibition
Limited solutions for high-resistance HIV strains

4. BIOLOGICAL RATIONALE

4.1 SCF Pathophysiological Targeting

Indevirate is designed to address core HIV fault architecture:

Pathogenic Node	Intervention
Viral RNA synthesis	Chain termination
Viral DNA integration	Integrase interference
Immune dysregulation	NF-κB modulation
Redox support of replication	Oxidative disruption

4.2 Mechanistic Differentiation

Dual-node viral inhibition:

RNA transcription blockade
Integration pathway disruption

Multi-system reinforcement:

Immune stabilization
Redox modulation
Sustained pharmacokinetic exposure

5. CANDIDATE MODALITY

5.1 Core Modality

Attribute	Description
Type	Small-molecule nucleoside analog derivative
Scaffold	Cordycepin-derived
Mechanism	Viral genome arrest

5.2 SCF Stack Architecture

Layer	Function
F1	Antiviral payload (Indevirate core)
F2	Safety harmonizer
F3	Metabolic stabilizers
F4	PK enhancers (LPNP delivery)
F5	System support agents

5.3 Delivery System

LPNP Platform:

Enhances oral bioavailability
Enables lymphatic targeting
Provides controlled release (12–24 hr profile)

6. DEVELOPMENT STAGE

6.1 Current Status

Stage	Status
Discovery (SCF Phases 1–4)	Completed
Preclinical Design (Phases 5–6)	Completed
Safety & Resistance Modeling (Phase 7)	Completed
Translational Blueprint (Phase 8)	Completed

Overall: IND-Enabling Stage

7. NEXT EXPERIMENT

7.1 Immediate Priority Studies

Study	Objective
In vitro antiviral assay	Confirm viral suppression potency
HIV resistance selection assay	Validate mutation barrier
PK/PD rodent model	Establish dose-response
Biodistribution study	Confirm lymphatic targeting
GLP toxicology (dose-escalation)	Safety validation

7.2 Key Experimental Hypothesis

Indevirate will demonstrate:

≥2 log reduction in viral RNA
Sustained intracellular activity
Reduced emergence of resistant variants

8. GO / NO-GO CRITERIA

8.1 Go Criteria

Parameter	Threshold
Antiviral efficacy	≥2 log viral reduction
Resistance barrier	No dominant mutation after serial passaging
PK profile	Half-life ≥12 hrs
Safety	Acceptable GLP toxicology margins
Bioavailability	≥50% oral

8.2 No-Go Triggers

Risk	Threshold
Rapid resistance emergence	<3 passages
Toxicity	Dose-limiting adverse events
Poor PK	Half-life <6 hrs
Off-target effects	Significant host DNA interference

9. INTENDED PARTNER PROFILE

9.1 Target Partner Types

Partner Type	Role
Large Pharma (HIV franchise)	Clinical development & commercialization
Biotech (antiviral focus)	Co-development
CDMO (nanoparticle expertise)	Manufacturing scale-up
Academic institutions	Mechanistic validation

9.2 Ideal Partner Capabilities

HIV clinical trial infrastructure
Experience with antiretroviral drug development
Nanoparticle formulation and scale-up
Regulatory expertise (IND/NDA pathway)

9.3 Partnership Models

Co-development agreement
Licensing (regional/global)
Joint IND submission program

10. VALUE PROPOSITION

10.1 Differentiation

SCF-engineered multi-target antiviral system
High resistance barrier vs single-target ART
Reservoir-focused therapeutic strategy
Optimized PK via nanoparticle delivery

10.2 Strategic Impact

Indevirate has potential to:

Extend durability of HIV treatment
Reduce resistance-driven failure
Contribute to functional cure strategies

11. PROGRAM STATUS SUMMARY

Category	Status
Scientific Validation	Strong (multi-phase SCF pipeline)
Mechanistic Clarity	High
Translational Readiness	IND-enabling
Commercial Potential	High

12. CONTACT / PROGRAM ACCESS

Program Access Level: Controlled (Partner Evaluation Required)

Data Room: Available upon request

Next Milestone: IND submission readiness package

INDEVIRATE — SCF-ENGINEERED ANTIVIRAL API SCIENTIFIC BRIEF

Phase 8 Deliverable: Translational Blueprinting (Biomarkers, Clinical Endpoints, IND Strategy)

Phase 7 Deliverable: Resistance Prevention & Safety Modeling

Phase 6 Deliverable: Formulation Design & Pharmacokinetic Modeling

Phase 5 Deliverable: Reverse Engineering & Pathway Realignment

Phase 4 Deliverable: SCF Fibonacci Therapeutic Stack Design

Phase 3 Deliverable: Synergy Metrics Computation (TSSM, HSV-F², SV-EQ, MGIS, SPCI)

Phase 2 Deliverable: Bioactive Compound Extraction & SCF Analysis

Phase 1 Deliverable Only: Discovery & Ethnopharmacological Scouting